Innovating Works
HORIZON-HLTH-2024-DISEASE-17-01
HORIZON-HLTH-2024-DISEASE-17-01: Pandemic preparedness and response: Maintaining and enhancing the preparatory work for a co-funded European partnership for pandemic preparedness
Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:
Sólo fondo perdido 0 €
Europeo
Esta convocatoria está cerrada Esta línea ya está cerrada por lo que no puedes aplicar. Cerró el pasado día 30-05-2024.
Se espera una próxima convocatoria para esta ayuda, aún no está clara la fecha exacta de inicio de convocatoria.
Hace más de 13 mes(es) del cierre y aún no tenemos información sobre los proyectos financiados, no parece que se vaya a publicar esta información.
Presentación: Consorcio Consorcio: Esta ayuda está diseñada para aplicar a ella en formato consorcio.
Número mínimo de participantes.
Esta ayuda financia Proyectos:

Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:

Investments in research and innovation on pandemic preparedness are balanced and better co-ordinated along the whole research continuum from basic research, over pre-clinical research to clinical research;Research funders, policymakers and the research community dispose of an enhanced research and innovation framework for the European partnership for pandemic preparedness, including the Partnership’s objectives, governance and ways of working/operationalisation;Research funders, policymakers and the research community are aligned towards common objectives and have a common understanding of the long-term Strategic Research and Innovation Agenda for the Partnership;Research funders, policymakers and the research community work towards a valued network of clinical trial sites that has the capacity to implement well-... ver más

Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:

Investments in research and innovation on pandemic preparedness are balanced and better co-ordinated along the whole research continuum from basic research, over pre-clinical research to clinical research;Research funders, policymakers and the research community dispose of an enhanced research and innovation framework for the European partnership for pandemic preparedness, including the Partnership’s objectives, governance and ways of working/operationalisation;Research funders, policymakers and the research community are aligned towards common objectives and have a common understanding of the long-term Strategic Research and Innovation Agenda for the Partnership;Research funders, policymakers and the research community work towards a valued network of clinical trial sites that has the capacity to implement well-coordinated large-scale multi-country quality trials in different target populations, which are able to smoothly transition to public health interventions relevant for cross-border health threats in response to a public health emergency;Healthcare providers, European and international stakeholders engage with an extended number of EU-wide appropriate partners through the research and innovation framework for the partnership. Scope:The COVID-19 pandemic illustrated how unilateral research initiatives may lead to a fragmented research landscape, with substantial room for efficiency gains in the development of the highly needed evidence to guide policy actions when facing an emergency. A coordination and support action[1] is working towards improving the EU’s preparedness to predict and respond to emerging infectious health threats by better coordinating funding for research and innovation at EU, national (and regional) level towards common objectives and an agreed Strategic Research and Innovation Agenda. This work should be complemented by efforts towards establishing, maintaining and enhancing a network of ever-warm clinical trials sites and infrastructures for clinical research, ready to be pivoted in case of a pandemic or epidemic episode. In addition, this work should be extended to additional partners, primarily from the EU and Horizon Europe associated countries. Participation from widening countries should be ensured, promoting an inclusive approach in the design and governance of the partnership.

The partnership will contribute to building a coherent European Research Area (ERA), enabling Member States, Associated Countries and the European Commission to rapidly and jointly support research and innovation in pandemic preparedness.

The Partnership is expected to continue to build on existing pandemic preparedness networks and research infrastructures and work in synergy with the Health Emergency Preparedness and Response Authority (HERA).

Proposals should include all of the following activities:

Provide administrative and organisational support to prepare, ensure a smooth start and transition towards the European partnership for pandemic preparedness that will eventually take over these tasks;Actively engage with relevant stakeholders and initiatives in the area of pandemic preparedness, ensuring collaboration and coordination, and avoiding duplication; e.g. the Global Health EDCTP3 Joint Undertaking, GloPID-R, WHO R&D blueprint, ACT Accelerator, etc.;Implement strong communication and dissemination activities at EU level and in Member States and Associated Countries, on the purpose, activities and outputs of the European partnership for pandemic preparedness, ensuring a continuous dialogue, both outside and during epidemic/pandemic episodes;As relevant, apply a cross-cutting, interdisciplinary One Health approach. This topic requires the effective contribution of social sciences and humanities (SSH) disciplines and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities.

[1] Project BE READY / grant agreement number 101057795, funded under topic HORIZON-HLTH-2021-DISEASE-04-06 "Building a European partnership for pandemic preparedness".

ver menos

Temáticas Obligatorias del proyecto: Temática principal: Biological weapons (anthrax botulism…) Surveillance Mosquito Tick Veterinary medicine and infectious diseases in ani Transmission mechanism Transmission Helminths Smallpox Prions Clinical trials Statistics in clinical trials Phase III Clinical information Virology Chikingunya Influenza Emerging Epidemics Fungi Clinical research Clinical development Phase III Social sciences and humanities Protozoa Crimean Congo Haemorrhagic Fever Statistics in clinical trials Phase IV Dengue Prevention and treatment of infection by pathogens Interventional clinical trials Severe acute respiratory syndrome Bacteriology Microbiology Pathogen agents Cohort studies Disease control Public health and epidemiology Drug development clinical phases Drug development late phases Clinical data Clinical targets Vector control Hepatitis Statistics in clinical trials Phase II Clinical development Phase II Viral Haemorrhagic Fevers Preparedness Bacteria Infectious diseases Clinical development Phase I SARS Virulence Viruses West Nile Statistics in clinical trials Phase I Biological weapons Veterinary medicine and infectious diseases in animals Chikungunya Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Clinical Trials Epidemiology Infectious Diseases Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I Statistics in clinical trials Phase IV Statistics in clinical trials Phase II Statistics in clinical trials Phase I

Características del consorcio

Ámbito Europeo : La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Tipo y tamaño de organizaciones: El diseño de consorcio necesario para la tramitación de esta ayuda necesita de:

Características del Proyecto

Requisitos de diseño por participante: *Presupuesto para cada participante en el proyecto
Requisitos técnicos: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:
Capítulos financiables: Los capítulos de gastos financiables para esta línea son:
Personnel costs.
Gastos relacionados con el personal que trabaja directamente en el proyecto basado en las horas efectivas dedicadas, basado en el coste empresa y ratios fijos para determinados empleados como los dueños de la compañía.
Subcontracting costs.
Pagos a terceros externos para realizar tareas específicas que no pueden ser realizadas por los beneficiarios del proyecto.
Purchase costs.
Incluyen la adquisición de equipos, amortizaciones, material, licencias u otros bienes y servicios necesarios para la ejecución del proyecto
Other cost categories.
Gastos diversos como costes financieros, certificados de auditoría o participación en eventos no cubiertos por otras categorías
Indirect costs.
Gastos generales no asignables directamente al proyecto (como electricidad, alquiler u oficina), calculados como un 25% fijo sobre los costes directos elegibles (excepto subcontratación).
Madurez tecnológica: La tramitación de esta ayuda requiere de un nivel tecnológico mínimo en el proyecto de TRL 9:. En esta fase la innovación está en su fase final y es operable en un sin número de condiciones operativas, está probada y disponible para su comercialización y/o producción disponible para la sociedad. Entrega de producto o tecnología para producción en serie y comercialización. + info.
TRL esperado:

Características de la financiación

Intensidad de la ayuda: Sólo fondo perdido + info
Fondo perdido:
Para el presupuesto subvencionable la intensidad de la ayuda en formato fondo perdido podrá alcanzar como minimo un 100%.
The funding rate for CSA projects is 100 % of the eligible costs for all types of organizations. The funding rate for CSA projects is 100 % of the eligible costs for all types of organizations.
Garantías:
No exige Garantías
No existen condiciones financieras para el beneficiario.

Información adicional de la convocatoria

Efecto incentivador: Esta ayuda no tiene efecto incentivador. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
No Competitiva Competitiva Muy Competitiva
No conocemos el presupuesto total de la línea
Minimis: Esta línea de financiación NO considera una “ayuda de minimis”. Puedes consultar la normativa aquí.
Certificado DNSH: Los proyectos presentados a esta línea deben de certificarse para demostrar que no causan perjuicio al medio ambiente. + info

Otras ventajas

Sello PYME: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
HORIZON-HLTH-2024-DISEASE-17 Pandemic preparedness and response: Maintaining and enhancing the preparatory work for a co-funded European partnership for pandemic preparedness Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destinatio...
Sin info.
HORIZON-HLTH-2024-DISEASE-13-01 Implementation research for management of multiple long-term conditions in the context of non-communicable diseases (Global Alliance for Chronic Diseases - GACD)
en consorcio: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destinatio...
Cerrada hace 7 meses | Próxima convocatoria prevista para el mes de
HORIZON-HLTH-2024-DISEASE-12-01 European partnership for pandemic preparedness
en consorcio: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destinatio...
Cerrada hace 7 meses | Próxima convocatoria prevista para el mes de
HORIZON-HLTH-2024-DISEASE-09-01 European Partnership: One Health Anti-Microbial Resistance
en consorcio: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destinatio...
Cerrada hace 9 meses | Próxima convocatoria prevista para el mes de
HORIZON-HLTH-2024-DISEASE-17-01 Pandemic preparedness and response: Maintaining and enhancing the preparatory work for a co-funded European partnership for pandemic preparedness
en consorcio: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destinatio...
Cerrada hace 1 año | Próxima convocatoria prevista para el mes de
HORIZON-HLTH-2024-DISEASE-08-20 Pandemic preparedness and response: Host-pathogen interactions of infectious diseases with epidemic potential
en consorcio: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destinatio...
Cerrada hace 1 año | Próxima convocatoria prevista para el mes de